Bright Minds Biosciences Inc (DRUG) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access DRUG Annual Cash Flow →
From Bright Minds Biosciences Inc through Sep 30 2024, changes in Sep 30 2025's operating cash flow provide insight into underlying business performance trends.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2025)
12 Months
0 0 0 (Sep 30 2024)
Operating Activities
Income-9.37
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Adjustments For Unrealised Foreign Exchange Losses Gains-0.24
Adjustments For Depreciation And Amortisation Expense-
Adjustments For Decrease Increase In Sales Tax Receivable-
Adjustments For Decrease Increase In Trade And Other Receivables-
Adjustments For Decrease Increase In Prepaid Expenses-
Adjustments For Increase Decrease In Trade Account Payable-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities2.47
Discontinued operations0.00
Net Cash flow from Operating Activities-6.66
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net63.56
Increase Decrease In Cash And Cash Equivalents-
Proceeds From Exercise Of Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities65.54
Effect of exchange rate on cash flow58.89
Discontinued operations0.00
Free Cash Flow-6.66
Total Cash Flow4.38
4 historic quarters locked

Sign in to unlock the full Bright Minds Biosciences Inc cash flow history.

About Bright Minds Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 40-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-25-038729

Figures are derived from filed reports and may be restated. Historical data is subject to revision.